API Packaging Assembly for Nitrosamine-Controlled Storage

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing active pharmaceutical ingredients (APIs) face the challenge of nitrosamine impurities, particularly 1-methyl-4-nitrosopiperazine (MeNP), 1-cyclopentyl-4-nitrosopiperazine, and N-Nitroso-3-azabicyclo[3.3.0]octane, which increase over time during storage, leading to non-compliance with regulatory limits.

Innovation Solution

A packaging method and assembly using thermoplastic and aluminum-based bags with oxygen-scavenging and moisture-absorbing agents under inert gas atmosphere to maintain nitrosamine levels below predetermined thresholds.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of stationary object

If APIs are stored under conventional conditions, then storage duration is extended, but nitrosamine impurity levels increase over time leading to regulatory non-compliance

Engineering Contradiction:

Improvestorage durationVSAvoidnitrosamine impurity formation

Core Design Contradiction:

Duration of action of stationary objectVSObject-generated harmful factors

Solution Approach 1:

The patent applies inert atmosphere by replacing air with nitrogen gas in the storage container, creating an oxygen-free environment that prevents oxidation of rifampicin to nitrosopiperazine. This resolves the contradiction by enabling long-term storage without nitrosamine formation, as the inert atmosphere eliminates the oxidizing conditions that would otherwise generate impurities over time.

Inventive Principle:

Principle #39Inert atmosphere (Inert environment)

Solution Approach 2:

The patent introduces an oxygen scavenger as an intermediary substance that actively removes residual oxygen from the storage environment. This mediator prevents direct contact between oxygen and rifampicin, thereby blocking the oxidation pathway to nitrosamines while maintaining extended storage duration without compliance issues.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Manufacturing precision

If purification processes are intensified to reduce initial nitrosamine content, then manufacturing precision improves, but production complexity and cost increase

Engineering Contradiction:

Improvenitrosamine content controlVSAvoidpurification process complexity

Core Design Contradiction:

Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent applies preliminary action by implementing preventive storage measures (inert atmosphere and oxygen scavengers) from the outset, rather than requiring extensive post-synthesis purification. This approach achieves low nitrosamine content through prevention during storage, avoiding the need for complex additional purification steps while maintaining manufacturing efficiency.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method and assembly effectively maintain nitrosamine levels within regulatory limits for at least six months, ensuring API compliance during storage.

Implementation Method 1

storing said rifampicin in an inert gas atmosphere

Methodology Applied

Scientific EffectInert atmosphere:

Implementation Method 2

presence of an oxygen scavenger in said storage container

Methodology Applied

Scientific EffectOxygen scavenging:

Implementation Method 3

presence of a moisture absorber in said storage container

Methodology Applied

Scientific EffectMoisture absorption: Absorption (physical)

Data Source

PatentUS20260000577A1Methods and assemblies for control of formation of nitrosamine impurities in solid active pharmaceutical ingredients

Publication Date: 2026.01.01 OLON SPA

AI summary

The present invention relates to the field of impurities control, in particular genotoxic impurities, in active pharmaceutical ingredients (APIs).In particular, the present invention relates to a packaging method and assembly for the control of the formation of a nitrosamine, for example 1-methyl-4-nitrosopiperazine (MeNP), in a solid active pharmaceutical ingredient (API), for example rifampicin, during storage.